Cardiac Marker Testing Market worth $ 3.50 Billion by 2021

Pune, India , 2020-Feb-21 — /EPR Network/ —

The report Cardiac Marker Testing Market by Type (Troponin I & T, CK-MB, Myoglobin, BNP, hsCRP), Product (Reagent, Instrument), Method (Chemiluminescence, ELISA), Disease (Myocardial Infarction, Congestive Heart Failure), Testing (Lab, POC) – Global Forecast to 2021″ , analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-Pacific, and the Rest of the World (RoW).

Download Free PDF Brochure :

This report studies the global cardiac marker testing market over the forecast period of 2016 to 2021. The market is expected to reach ~USD 3.50 Billion by 2021, at a CAGR of 8.8% from 2016 to 2021. A number of factors such as growing incidences of cardiovascular diseases, the rapidly increasing geriatric population, growing funding from public–private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers are fueling the growth of the cardiac marker testing market. On the other hand, technical problems related to sample collection and storage and issues related to regulatory and reimburse systems are some of the key factors limiting the growth of the global cardiac marker testing market.

Based on type, the global cardiac marker testing market is divided into six segments, namely, troponin I and T, CK-MB, BNP or NT-proBNP, Myoglobin, hsCRP, and other biomarkers. The other biomarkers segment includes galectin-3, H-FABP, myeloperoxidase, ischemia-modified albumin, and homocysteine.

On the basis of product, the global cardiac marker testing market is segmented into reagents and kits and instruments. The instruments section is further segmented on the basis of method, namely, chemiluminescence, immunofluorescence, ELISA, and immunochromatography. On the basis of disease, the cardiac marker testing market is segmented into myocardial infarction and congestive heart failure. On the basis of type of testing, the cardiac marker testing market is segmented into laboratory testing and point-of-care testing.

As of 2016, North America held the largest share of the global cardiac marker testing market, followed by Europe. However, the Asia-Pacific market is expected to register the highest CAGR of 11.7% from 2016 to 2021. Factors such as rising prevalence and incidence of cardiovascular diseases and public-private initiatives to increase awareness about early cardiac disease diagnosis are stimulating the growth of the cardiac marker testing market in the Asia-Pacific region.

Speak to Analyst :

Roche Diagnostics Ltd. (Switzerland), Abbott Laboratories (U.S.), Siemens AG (Germany), Danaher Corporation (U.S.) Alere, Inc. (U.S.), bioMérieux SA (France), LSI Medience Corporation (a subsidiary of Mitsubishi Chemical Holdings Corporation, Japan), Ortho Clinical Diagnostics (a subsidiary of The Carlyle Group, U.S.), Randox laboratories Ltd (U.K.), and Guangzhou Wondfo Biotech Co., Ltd. (Wondfo) (China) are some of the key players operating in the global cardiac marker testing market.

About MarketsandMarkets

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “RT” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Mr. Sanjay Gupta

MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441

Matched content

Editor’s pick

Do NOT follow this link or you will be banned from the site!